Pharma and healthcare mutual funds have yielded impressive returns in 2024. The sector benefited from resilience amidst corrections in other sectors and steady growth in the domestic market. Experts suggest a cautious approach to investment due to current valuations. A phased allocation strategy of 10-15% is recommended, with potential for increasing allocation over time. Pharma and healthcare mutual funds have yielded impressive returns in 2024. The sector benefited from resilience amidst corrections in other sectors and steady growth in the domestic market. Experts suggest a cautious approach to investment due to current valuations. A phased allocation strategy of 10-15% is recommended, with potential for increasing allocation over time. Economic Times
Headlines
